TKG Therapeutics
Latest round
- Seed
Last raised
- Jan 2024
Total raised
- $0.5M
Investors
- 2
About TKG Therapeutics
Founded in 2022 and based in Tokyo, Japan, TKG Therapeutics, Inc. is a research and developer of cancer immunity drugs. As of 2024, the company is headed by its CEO Masaaki Matsui. The company offers nucleic acid-derived cancer medicine that will allow natural immunity to fight the disease. To create nucleic acid aggregates that target disease cells and are identified as foreign substances, the company pharmaceuticals employ miRNA, which is specifically overexpressed in cancer cells, as a biomarker. This triggers innate immunity and ultimately results in cancer cell death.
Who invested in TKG Therapeutics
2 investors across 1 round
See all investors in TKG Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jan 31, 2024
Amount
$0.5M
Investors
Questions about TKG Therapeutics
Who invested in TKG Therapeutics?
TKG Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TKG Therapeutics raised?
TKG Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did TKG Therapeutics last raise money?
TKG Therapeutics's most recent round on record is a Seed, in Jan 2024.
What does TKG Therapeutics do?
Founded in 2022 and based in Tokyo, Japan, TKG Therapeutics, Inc.
Where is TKG Therapeutics headquartered?
TKG Therapeutics is headquartered in Tokyo, Japan.
Which VCs invest in companies like TKG Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at TKG Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like TKG Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.